SGLT-2抑制剂治疗心力衰竭的最新研究进展  

Latest research progress of SGLT-2 inhibitors in treatment of heart failure

作　　者：温瑶 张瑶[1] WEN Yao;ZHANG Yao(Department of Cardiology,Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150081,China)

机构地区：[1]哈尔滨医科大学附属第二医院心内科,黑龙江哈尔滨150081

出　　处：《心血管康复医学杂志》2024年第3期357-361,共5页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：心力衰竭是各种心脏疾病的严重表现形式或终末阶段,死亡率及再住院率居高不下。因此如何改善患者预后、提高患者生活质量等问题,成为当今研究热点。钠-葡萄糖共转运蛋白2抑制剂(sodium-glucose cotransporter 2 inhibitors,SGLT2i)作为一种新型降糖药,已被多个实验证明可以改善心衰患者的预后。本文旨在从作用机制、临床研究、最新临床指南等方面进行阐述、以期为心衰患者提供更好的治疗。Heart failure is a serious manifestation or terminal stage of various heart diseases,with high mortality and rehospitalization rate.Therefore,how to improve patients'prognosis and quality of life etc.has become a research hotspot.As a new hypoglycemics,sodium-glucose cotransporter 2 inhibitor has been proved by many experiments to improve the prognosis of patients with heart failure.This article aims to elaborate it from aspects of mechanism,clinical research and the latest clinical guidelines in order to provide better treatment for patients with heart failure.

关 键 词：心力衰竭 钠-葡萄糖共转运蛋白2抑制剂 治疗 

分 类 号：R541.6[医药卫生—心血管疾病]